INSTAGE: A Randomized Trial of Nintedanib Plus Sildenafil Versus Nintedanib Alone in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment

被引：0
|
作者：
Kolb, M. R. [1 ]
Wells, A. [2 ,3 ]
Behr, J. [4 ,5 ]
Richeldi, L. [6 ]
Schnaidt, S. [7 ]
Quaresma, M. [7 ,8 ]
Stowasser, S. [7 ]
Raghu, G. [9 ]
Martinez, F. J. [10 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
[2] Imperial Coll, Natl Inst Hlth Res Resp Biomed Res Unit, Royal Brompton & Harefield NHS Fdn Trust, London, England
[3] Imperial Coll, Natl Heart & Lung Inst, London, England
[4] Univ Munich LMU, Med Klin & Poliklin 5, Munich, Germany
[5] Asklepios Klin Munchen Gauting, German Ctr Lung Res, Munich, Germany
[6] Univ Cattolica Sacro Cuore, Fdn Policlinico A Gemelli, Rome, Italy
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[8] Heidelberg Univ, Thoraxklin, Ctr Interstitial & Rare Lung Dis, Pneumol & Resp Care Med, Heidelberg, Germany
[9] Univ Washington, Seattle, WA 98195 USA
[10] Weill Cornell Med Coll, New York, NY USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1645
引用
收藏
页数：2
相关论文
共 50 条
  • [21] HEPATIC DISORDERS OF PIRFENIDONE OR NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) A SYSTEMATIC REVIEW
    Singla, D.
    Mahapatra, S.
    Dey, A.
    John, A.
    VALUE IN HEALTH, 2022, 25 (12) : S218 - S218
  • [22] Effect of Nintedanib on Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis (IPF): Results from a Phase IIIb Trial
    Lancaster, L. H.
    Conoscenti, C. S.
    Ilowite, J.
    Trampisch, M.
    Mogulkoc, N.
    Homik, L.
    Kaye, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [23] Baseline Lung Function Had No Effect on Long-Term Reduction in FVC Decline With Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Kaye, Mitchell
    Mohabir, Paul
    Hotchkin, David
    Gibson, Kevin
    Stansen, Wibke
    Quaresma, Manuel
    Crestani, Bruno
    CHEST, 2017, 152 (04) : 453A - 453A
  • [24] Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis
    Ikeda, Satoshi
    Ogura, Takashi
    Kato, Terufumi
    Kenmotsu, Hirotsugu
    Agemi, Yoko
    Tokito, Takaaki
    Ito, Kentaro
    Isomoto, Kohsuke
    Takiguchi, Yuichi
    Yoneshima, Yasuto
    Yokoyama, Toshihide
    Harada, Toshiyuki
    Tanzawa, Shigeru
    Kobayashi, Nobuaki
    Iwasawa, Tae
    Misumi, Toshihiro
    Okamoto, Hiroaki
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (04) : 635 - 643
  • [25] Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial
    Otsubo, Kohei
    Kishimoto, Junji
    Ando, Masahiko
    Kenmotsu, Hirotsugu
    Minegishi, Yuji
    Horinouchi, Hidehito
    Kato, Terufumi
    Ichihara, Eiki
    Kondo, Masashi
    Atagi, Shinji
    Tamiya, Motohiro
    Ikeda, Satoshi
    Harada, Toshiyuki
    Takemoto, Shinnosuke
    Hayashi, Hidetoshi
    Nakatomi, Keita
    Kimura, Yuichiro
    Kondoh, Yasuhiro
    Kusumoto, Masahiko
    Ichikado, Kazuya
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Nakanishi, Yoichi
    Okamoto, Isamu
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60 (06)
  • [26] Nintedanib Attenuates Motility Of Lung Fibroblasts From Patients With Idiopathic Pulmonary Fibrosis
    Wollin, L.
    Ostermann, A.
    Wex, E.
    Herrmann, F. E.
    Doods, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [27] SAFETY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): LONG-TERM GLOBAL PHARMACOVIGILANCE DATA
    Lasky, Joseph
    Criner, Gerard
    Lazarus, Howard
    Kohlbrenner, Veronika
    Bender, Shaun
    Richeldi, Luca
    CHEST, 2019, 156 (04) : 1011A - 1012A
  • [28] Relationship between nintedanib exposure, clinical efficacy and adverse events in patients with idiopathic pulmonary fibrosis (IPF)
    Schmid, U.
    Weber, B.
    Dallinger, C.
    Richeldi, L.
    Hallmann, C.
    Raghu, G.
    Freiwald, M.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S42 - S42
  • [29] Characteristics of patients with idiopathic pulmonary fibrosis (IPF) initiating nintedanib or pirfenidone treatment compared with untreated patients in the US
    Near, Aimee M.
    Burudpakdee, Chakkarin
    Wallace, Laura
    Hartmann, Nadine
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 163 - 164
  • [30] Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials
    Azuma, Arata
    Taniguchi, Hiroyuki
    Inoue, Yoshikazu
    Kondoh, Yasuhiro
    Ogura, Takashi
    Homma, Sakae
    Fujimoto, Tsuyoshi
    Sakamoto, Wataru
    Sugiyama, Yukihiko
    Nukiwa, Toshihiro
    RESPIROLOGY, 2017, 22 (04) : 750 - 757
12345